Vol. 1 Issue 04      Friday, September 14, 2007 Visit us at CPhI Worldwide 2007 at Fiera di Milano, Italy,  October 2 - 4  2007,  at Hall 14, Stand No: 14H09  Business Development at Calyx, Japan Mr. Isao Mori – Business Development, is our  link  between   Japanese  Pharmaceutical customers and Calyx’s Indian  operations. Mr. Mori, a Japanese  citizen  and  resident of Tokyo, is a Calyx team   member.  He  joined   the Calyx family  after  working  for  thirty years with Mochida Pharmaceutical Co. Ltd. in different capacities. His varied experience in  pharmaceutical   industry  involves   functions  like  Product  development,  Licensing,   Patent  Management, Sales and others. He  is constantly in contact  with our customers in Japan to understand and cater to  their product requirements.  Mr. Isao Mori Mr. Mori manages our business in Japan with the able secretarial support of Mrs.Kazuko Yamamoto.    Our Commitment to Environment Calyx's challenge for the new  millennium is to learn  how  to live in harmony  with the environment.  We are  looking at  Environment, health &  safety  (EHS)   excellence   as   competitive   advantage  in  today's  business   scenario. Considerable changes are taking  place in Calyx's EHS  programs, including  enhancement  of  our  EHS policy and adoption of ISO 14001, an Environmental Management System. We  have established, implemented ISO 14001 and gone   through  main  certification process. To set an  equilibrium, we  are  also  strengthening  the  safety &  health aspects of our EHS Management System. Our EHS objectives and improvement plans: •   Zero occupational accidents /injuries - to  create a workplace, strengthen  EHS systems and  train the workforce,     to free them of occupational injuries and illnesses. •   Continual  improvement of EHS processes - we  have ETP upgradation plans to meet new  consent requirements     and plans to build storage facilities to meet requirements. We have plans to improve process safety. •   Developing & influencing  vendors /suppliers to adopt better  EHS management system - our audit  team evaluate      EHS and quality gaps. •   Evaluating & controlling environmental and safety impact of purchased goods, systems and services. •   Evaluating EHS aspect and incorporating better  prevention during  design  of  products,  processes and facilities     - our R&D, Pilot Plant & project teams identify the environmental  aspects at  design stage and institute  controls,     as necessary. •   Conservation of natural resources By  adopting  the  path  of   EHS excellence,  Calyx  has embarked  on  a   challenging   journey -  the  journey to a sustainable world. …Calyx EHS Policy   APIs Commercial Scale Alendronate sodium Arteether Artemether Artesunate Azithromycin Cetirizine dihydrochloride Chloramphenicol palmitate Clopidogrel bisulphate Coenzyme Q10 Dihydroartemisinin Erythromycin base Erythromycin estolate Erythromycin ethyl succinate Erythromycin oxime (intermediate) Erythromycin phosphate Erythromycin propionate Erythromycin stearate Isoniazid Lisinopril dihydrate Losartan potassium Pyrazinamide Rifampicin Roxithromycin Sodium valproate Valproic acid Venlafaxine hydrochloride Zoledronic acid Zopiclone Pilot Plant Scale Carvedilol Clarithromycin Pioglitazone hydrochloride Rosiglitazone maleate Valsartan R & D Scale Lumefantrine Pamidronate disodium Perindopril erbumine Zolpidem tartrate Development Benazepril hydrochloride Candesartan Desvenlafaxine Glipizide Irbesartan Levocetirizine Rifabutin Rifapentine Ramipril Risedronic acid Telmisartan Products  under  patent  offered  only  for  exempted research, clinical and development purposes. Only non-infringing poducts  and  processes are  offered,  subject to patent status verification by client. Services   Disclaimer:  "The information in this e-mail and any attachments is confidential and may be legally privileged. It is intended solely for the addressee or addressees. If you are not an intended recipient, please delete the  message and any   attachments and notify the sender of  misdelivery. Any use or disclosure of  the  contents of either is unauthorized  and  may   be unlawful. All  liability  for viruses is excluded to the fullest   extent permitted by law. Any views   expressed in this message  are those of the individual sender, except where the sender   states them, with requisite authority, to be those of the specific Calyx company." To unsubscribe from this Newsletter send blank email to pharmanews@calyxindia.com